StockData

NRX Pharmaceuticals vs Vistagen Therapeutics

NRXP and VTGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NRXP and VTGN compare

NRX Pharmaceuticals is the larger company, worth 13 times as much as Vistagen Therapeutics ($106M against $8.3M).

NRX Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −692% compared with −2703% at Vistagen Therapeutics.

Vistagen Therapeutics scores higher on the StockData Score (9 against 0 for NRX Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNRXPVTGN
Size and price
Market cap$106M$8.3M
Share price$2.45$0.188
Change, 1 year−1.6%−95.1%
Change, 5 years−96.4%−99.7%
Beta (5Y)1.151.50
Employees2941
StockData Score
Total score09 (better)
Valuation score03 (better)
Growth score00
Performance score01 (better)
Health score05 (better)
Dividend score00
Valuation
P/S31.3×3.3× (better)
P/B–0.3×
Fair value–$0.851
Margin of safety–77.9%
Growth
Revenue growth, 5Y average–3.1%
Profitability
Gross margin46.6%–
Operating margin−586% (better)−2784%
Net margin−692% (better)−2703%
Return on equity–−166%
Financial health
Debt / equity–0.00
Interest coverage−17.4×–
Current ratio0.863.07 (better)
Altman Z-score−13.45 (better)−24.35
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions26.9%26.5%
Held by insiders15.6%0.52%
Short interest, % of float28.6%5.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.